Ascletis to stop clinical testing of ASC42 in primary biliary cholangitis
Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…
Cholangitis
Featured resources
Cholangitis overview: What you should know
Cholangitis is a liver condition characterized by inflammation in the bile ducts, most commonly caused by a bacterial infection but also may develop due to a variety of other causes.
Read more
Cholangitis treatment and management options
A variety of treatments may be used to treat cholangitis, depending on the type and whether it is acute or chronic.
Read moreLatest news
Elafibranor for PBC may become Genfit’s first approved molecule
Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…
